Form 4: Amedisys Inc. Chief Accounting Officer Sells Shares

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., sold 2,041 shares of common stock at an average price of $92.03 on March 4, 2025.

Summary

• On March 4, 2025, Allyson Guidroz, the Chief Accounting Officer of Amedisys Inc., sold 2,041 shares of the company's common stock.
• The sale was executed at a weighted average price of $92.03 per share, with individual transactions ranging from $91.9577 to $92.10.
• Following the transaction, Guidroz directly owns 8,761 shares of Amedisys Inc.
• Guidroz also indirectly owns 1.5 shares through a 401(k) plan, based on a plan statement dated December 31, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to a stock sale by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• It's common for executives at publicly traded companies like Amedisys to periodically sell shares for personal financial management.
• The volume of shares sold (2,041) is relatively small compared to the total outstanding shares of Amedisys, suggesting it's unlikely to be a major market-moving event.
• Comparable companies in the healthcare services sector, such as LHC Group or Option Care Health, also see regular Form 4 filings from their executives.

Stakeholder Impact

• The sale of shares by a company executive can sometimes be perceived negatively by shareholders, but the relatively small volume of shares sold in this instance suggests minimal impact.

Key Dates